This means that manufacturers must satisfy the needs of PBMs in order to meet the needs of patients. !function(n){ if(!window.cnxps){ window.cnxps={},window.cnxps.cmd=[]; var t=n.createElement('iframe'); t.display='none',t.onload=function(){ var n=t.contentWindow.document,c=n.createElement('script'); c.src='//cd.connatix.com/connatix.playspace.js',c.setAttribute('defer','1'),c.setAttribute('type','text/javascript'),n.body.appendChild(c) },n.head.appendChild(t) } }(document); (function() { function createUniqueId() { return 'xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx'.replace(/[xy]/g, function(c) { var r = Math.random() * 16 | 0, v = c == 'x' ? r : (r & 0x3 | 0x8); return v.toString(16); }); } const randId = createUniqueId(); document.getElementsByClassName('fbs-cnx')[0].setAttribute('id', randId); document.getElementById(randId).removeAttribute('class'); (new Image()).src = 'https://capi.connatix.com/tr/si?token=546f0bce-b219-41ac-b691-07d0ec3e3fe1'; cnxps.cmd.push(function () { cnxps({ playerId: '546f0bce-b219-41ac-b691-07d0ec3e3fe1'}).render(randId); }); })();
Drugs not able to compete on quality / effectiveness; a therapy that might work for a patient may be off limits / they may be limited to an option that doesn't work for them, but is the one that's on the PBM formulary